Alan Levine - Axogen Director
| AXGN Stock | USD 6.41 0.25 3.75% |
Director
Mr. Alan M. Levine is appointed as Independent Director of the Company, effective May 15, 2019. Mr. Levine was the chairman, president, and chief executive officer of Ballad Health, an integrated health care delivery system. From January 2014 until January 2018, he served as the president and chief executive officer of Mountain States Health Alliance, the largest health system in upper east Tennessee and southwest Virginia. He served as a senior advisor to the Board of Directors, president of the Florida Group and corporate senior vice president during his July 2010 to January 2014 tenure at Health Management Associates, a hospital and health care facilities operator. From January 2008 until July 2010, Mr. Levine served as senior health policy advisor to Louisiana Governor Bobby Jindal, and as the Secretary of the Louisiana Department of Health and Hospitals on the Governors cabinet. He was the president and chief executive officer of the North Broward Hospital District, one of the largest public health and hospital systems in the nation, from July 2006 until January 2008. He also served as the secretary of the Florida Agency for Health Care Administration, the health planning and regulatory agency for the State of Florida with responsibility for the oversight of more than 30, 000 health care facilities, and the 17 billion state Medicaid program, from June 2004 until July 2006 since 2019.
| Age | 50 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 13631 Progress Boulevard, Alachua, FL, United States, 32615 |
| Phone | 386 462 6800 |
| Web | https://www.axogeninc.com |
Axogen Management Efficiency
The company has return on total asset (ROA) of (0.0684) % which means that it has lost $0.0684 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2208) %, meaning that it created substantial loss on money invested by shareholders. Axogen's management efficiency ratios could be used to measure how well Axogen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of May 2024, Return On Tangible Assets is likely to drop to -0.12. In addition to that, Return On Capital Employed is likely to grow to -0.12. At this time, Axogen's Debt To Assets are very stable compared to the past year. As of the 1st of May 2024, Asset Turnover is likely to grow to 0.95, though Non Currrent Assets Other are likely to grow to (83.2 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Charles Holliday | HCA Holdings | 73 | |
| Vicky Gregg | Acadia Healthcare | 63 | |
| Wayne Riley | HCA Holdings | 61 | |
| Annie Lamont | HCA Holdings | 60 | |
| Ann Lamont | HCA Holdings | 58 | |
| John Rowe | HCA Holdings | 72 | |
| William Frist | HCA Holdings | 51 | |
| Kyle Lattner | Acadia Healthcare | 29 | |
| Wade Miquelon | Acadia Healthcare | 53 | |
| William Grieco | Acadia Healthcare | 64 | |
| EPerot Bissell | Acadia Healthcare | 58 | |
| Robert Dennis | HCA Holdings | 67 | |
| Reeve Waud | Acadia Healthcare | 54 | |
| NancyAnn DeParle | HCA Holdings | 64 | |
| Christopher Gordon | Acadia Healthcare | 44 | |
| William Petrie | Acadia Healthcare | 71 | |
| Michael Michelson | HCA Holdings | 69 | |
| Meg Crofton | HCA Holdings | 67 | |
| Geoffrey Meyers | HCA Holdings | 73 | |
| Jay Light | HCA Holdings | 74 | |
| Chris Gordon | Acadia Healthcare | 44 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0684 |
Axogen Inc Leadership Team
Elected by the shareholders, the Axogen's board of directors comprises two types of representatives: Axogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axogen. The board's role is to monitor Axogen's management team and ensure that shareholders' interests are well served. Axogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Davault, VP Marketing | ||
| Mark Friedman, Vice President - Regulatory and Quality | ||
| John Engels, Co-Founder and VP | ||
| Jamie Grooms, Co-Founder, Chairman, Member of Audit Committee and Member of Governance and Nominating Committee | ||
| Shawn McCarrey, Sr. VP of Sales | ||
| Kevin Leach, Vice President - Marketing | ||
| Joseph Mandato, Independent Director | ||
| Mike Donovan, Director of Operations | ||
| CFA CPA, Chief Officer | ||
| Kaila Krum, Vice President Investor Relations and Corporate Development | ||
| Christopher Crisman, Vice President - U.S. Sales | ||
| Alan Levine, Director | ||
| Guido Neels, Director | ||
| Marc Began, General VP | ||
| Michael Donovan, Vice Operations | ||
| James Grooms, Independent Chairman of the Board | ||
| Doris Quackenbush, Vice Sales | ||
| Harold Tamayo, Vice Relations | ||
| Quentin Blackford, Director | ||
| Robert Rudelius, Independent Director | ||
| Angelo Scopelianos, Vice President - Research & Development | ||
| Peter Mariani, Ex CFO | ||
| Maria Martinez, Chief Human Resource Officer | ||
| Eric Sandberg, Chief Commercial Officer | ||
| Amy Wendell, Director | ||
| Erick DeVinney, Vice President of Clinical and Translational Sciences | ||
| Lisa Colleran, Director | ||
| Karen Zaderej, CEO and President and Director | ||
| Isabelle Billet, Chief Strategy and Business Development Officer | ||
| Jens Kemp, Chief Officer | ||
| Gregory Freitag, Senior Vice President - Business Development, General Counsel, Director | ||
| David Hansen, Corporate Controller | ||
| Bradley JD, G Officer | ||
| Ed Joyce, Director Relations | ||
| Jon Gingrich, Chief Commercial Officer | ||
| Mark Gold, Independent Director | ||
| Ivica MD, Chief Officer |
Axogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0684 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 329.01 M | ||||
| Shares Outstanding | 43.7 M | ||||
| Shares Owned By Insiders | 5.22 % | ||||
| Shares Owned By Institutions | 76.67 % | ||||
| Number Of Shares Shorted | 1.67 M | ||||
| Price To Earning | (47.07) X |
Pair Trading with Axogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axogen will appreciate offsetting losses from the drop in the long position's value.Moving together with Axogen Stock
| 0.68 | AHG | Akso Health Group | PairCorr |
Moving against Axogen Stock
| 0.93 | SNDA | Sonida Senior Living | PairCorr |
| 0.82 | JYNT | Joint Corp Financial Report 2nd of May 2024 | PairCorr |
| 0.8 | TNDM | Tandem Diabetes Care | PairCorr |
| 0.75 | GCTK | GlucoTrack | PairCorr |
| 0.61 | TLIS | Talis Biomedical Corp | PairCorr |
The ability to find closely correlated positions to Axogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axogen Inc to buy it.
The correlation of Axogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Axogen Inc information on this page should be used as a complementary analysis to other Axogen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Axogen Stock analysis
When running Axogen's price analysis, check to measure Axogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axogen is operating at the current time. Most of Axogen's value examination focuses on studying past and present price action to predict the probability of Axogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axogen's price. Additionally, you may evaluate how the addition of Axogen to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Axogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axogen. If investors know Axogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Revenue Per Share 3.708 | Quarterly Revenue Growth 0.187 | Return On Assets (0.07) | Return On Equity (0.22) |
The market value of Axogen Inc is measured differently than its book value, which is the value of Axogen that is recorded on the company's balance sheet. Investors also form their own opinion of Axogen's value that differs from its market value or its book value, called intrinsic value, which is Axogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axogen's market value can be influenced by many factors that don't directly affect Axogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Axogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.